Secretome-Based identification of TFPI2, A novel serum biomarker for detection of ovarian clear cell adenocarcinoma

Journal of Proteome Research

Volumn 12, Issue 10, 2013, Pages 4340-4350

  Arakawa, Noriaki ^a   Miyagi, Etsuko ^b   Nomura, Ayako ^a   Morita, Erina ^a   Ino, Yoko ^a   Ohtake, Norihisa ^c   Miyagi, Yohei ^d   Hirahara, Fumiki ^b   Hirano, Hisashi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOSOH CORPORATION   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

Author keywords

biomarker; clear cell adenocarcinoma; diagnosis; ovarian cancer; TFPI2

Indexed keywords

PLACENTA PROTEIN 5; TUMOR ANTIGEN;

ADULT; AGED; AMINO ACID SEQUENCE; AREA UNDER THE CURVE; ARTICLE; BIOINFORMATICS; CANCER DIAGNOSIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEOME; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885223699     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr400282j     Document Type: Article

References (46)

1. Cho, K. R.; Shih, Ie, M. Ovarian Cancer Ann. Rev. Pathol. 2009, 4, 287-313
2. Itamochi, H.; Kigawa, J.; Terakawa, N. Mechanisms of Chemoresistance and Poor Prognosis in Ovarian Clear Cell Carcinoma Cancer Sci. 2008, 99 (4) 653-658
3. Sugiyama, T.; Kamura, T.; Kigawa, J.; Terakawa, N.; Kikuchi, Y.; Kita, T.; Suzuki, M.; Sato, I.; Taguchi, K. Clinical Characteristics of Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy Cancer 2000, 88 (11) 2584-2589
4. Itamochi, H.; Kigawa, J.; Akeshima, R.; Sato, S.; Kamazawa, S.; Takahashi, M.; Kanamori, Y.; Suzuki, M.; Ohwada, M.; Terakawa, N. Mechanisms of Cisplatin Resistance in Clear Cell Carcinoma of the Ovary Oncology 2002, 62 (4) 349-353
5. Itamochi, H.; Kigawa, J.; Sugiyama, T.; Kikuchi, Y.; Suzuki, M.; Terakawa, N. Low Proliferation Activity May Be Associated with Chemoresistance in Clear Cell Carcinoma of the Ovary Obstet. Gynecol. 2002, 100 (2) 281-287
6. Suh, K. S.; Park, S. W.; Castro, A.; Patel, H.; Blake, P.; Liang, M.; Goy, A. Ovarian Cancer Biomarkers for Molecular Biosensors and Translational Medicine Exp. Rev. Mol. Diagn. 2010, 10 (8) 1069-1083
7. Kudoh, K.; Kikuchi, Y.; Kita, T.; Tode, T.; Takano, M.; Hirata, J.; Mano, Y.; Yamamoto, K.; Nagata, I. Preoperative Determination of Several Serum Tumor Markers in Patients with Primary Epithelial Ovarian Carcinoma Gynecol. Obstet. Invest. 1999, 47 (1) 52-57
8. Pectasides, D.; Fountzilas, G.; Aravantinos, G.; Kalofonos, C.; Efstathiou, H.; Farmakis, D.; Skarlos, D.; Pavlidis, N.; Economopoulos, T.; Dimopoulos, M. A. Advanced Stage Clear-Cell Epithelial Ovarian Cancer: The Hellenic Cooperative Oncology Group experience Gynecol. Oncol. 2006, 102 (2) 285-291
9. Meyer, T.; Rustin, G. J. Role of Tumour Markers in Monitoring Epithelial Ovarian Cancer Br. J. Cancer 2000, 82 (9) 1535-1538
10. Nagle, C. M.; Olsen, C. M.; Webb, P. M.; Jordan, S. J.; Whiteman, D. C.; Green, A. C. Endometrioid and Clear Cell Ovarian Cancers: A Comparative Analysis of Risk Factors Eur. J. Cancer 2008, 44 (16) 2477-2484
11. Morita, A.; Miyagi, E.; Yasumitsu, H.; Kawasaki, H.; Hirano, H.; Hirahara, F. Proteomic Search for Potential Diagnostic Markers and Therapeutic Targets for Ovarian Clear Cell Adenocarcinoma Proteomics 2006, 6 (21) 5880-5890
12. Kim, A.; Enomoto, T.; Serada, S.; Ueda, Y.; Takahashi, T.; Ripley, B.; Miyatake, T.; Fujita, M.; Lee, C. M.; Morimoto, K.; Fujimoto, M.; Kimura, T.; Naka, T. Enhanced Expression of Annexin A4 in Clear Cell Carcinoma of the Ovary and Its Association with Chemoresistance to Carboplatin Int. J. Cancer 2009, 125 (10) 2316-2322
13. Anderson, N. L.; Anderson, N. G.; Haines, L. R.; Hardie, D. B.; Olafson, R. W.; Pearson, T. W. Mass Spectrometric Quantitation of Peptides and Proteins Using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) J. Proteome Res. 2004, 3 (2) 235-244
14. Makridakis, M.; Vlahou, A. Secretome Proteomics for Discovery of Cancer Biomarkers J. Proteomics 2010, 73 (12) 2291-2305
15. Gorai, I.; Nakazawa, T.; Miyagi, E.; Hirahara, F.; Nagashima, Y.; Minaguchi, H. Establishment and Characterization of Two Human Ovarian Clear Cell Adenocarcinoma Lines from Metastatic Lesions with Different Properties Gynecol. Oncol. 1995, 57 (1) 33-46
16. Yanagibashi, T.; Gorai, I.; Nakazawa, T.; Miyagi, E.; Hirahara, F.; Kitamura, H.; Minaguchi, H. Complexity of Expression of the Intermediate Filaments of Six New Human Ovarian Carcinoma Cell Lines: New Expression of Cytokeratin 20 Br. J. Cancer 1997, 76 (7) 829-835
17. Ogawa, M.; Yanoma, S.; Nagashima, Y.; Okamoto, N.; Ishikawa, H.; Haruki, A.; Miyagi, E.; Takahashi, T.; Hirahara, F.; Miyagi, Y. Paradoxical Discrepancy between the Serum Level and the Placental Intensity of PP5/TFPI-2 in Preeclampsia and/or Intrauterine Growth Restriction: Possible Interaction and Correlation with Glypican-3 Hold the Key Placenta 2007, 28 (2-3) 224-232
18. Nakamura, K.; Igarashi, K.; Ide, K.; Ohkawa, R.; Okubo, S.; Yokota, H.; Masuda, A.; Oshima, N.; Takeuchi, T.; Nangaku, M.; Okudaira, S.; Arai, H.; Ikeda, H.; Aoki, J.; Yatomi, Y. Validation of an Autotaxin Enzyme Immunoassay in Human Serum Samples and Its Application to Hypoalbuminemia Differentiation Clin. Chim. Acta; Int. J. Clin. Chem. 2008, 388 (1-2) 51-58
19. Gadducci, A.; Ferdeghini, M.; Cosio, S.; Fanucchi, A.; Cristofani, R.; Genazzani, A. R. The Clinical Relevance of Serum CYFRA 21-1 Assay in Patients with Ovarian Cancer Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc. 2001, 11 (4) 277-282
20. Fung, E. T. A Recipe for Proteomics Diagnostic Test Development: The OVA1 Test, From Biomarker Discovery to FDA Clearance Clin. Chem. 2010, 56 (2) 327-329
21. Luo, L. Y.; Soosaipillai, A.; Grass, L.; Diamandis, E. P. Characterization of Human Kallikreins 6 and 10 in Ascites Fluid from Ovarian Cancer Patients Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med. 2006, 27 (5) 227-234
22. Zorn, K. K.; Bonome, T.; Gangi, L.; Chandramouli, G. V.; Awtrey, C. S.; Gardner, G. J.; Barrett, J. C.; Boyd, J.; Birrer, M. J. Gene Expression Profiles of Serous, Endometrioid, And Clear Cell Subtypes of Ovarian and Endometrial Cancer Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11 (18) 6422-6430
23. Rao, C. N.; Reddy, P.; Liu, Y.; O'Toole, E.; Reeder, D.; Foster, D. C.; Kisiel, W.; Woodley, D. T. Extracellular Matrix-Associated Serine Protease Inhibitors (Mr 33,000, 31,000, and 27,000) are Single-Gene Products with Differential Glycosylation: cDNA Cloning of the 33-kDa Inhibitor Reveals Its Identity to Tissue Factor Pathway Inhibitor-2 Arch. Biochem. Biophys. 1996, 335 (1) 82-92
24. Sato, N.; Tsunoda, H.; Nishida, M.; Morishita, Y.; Takimoto, Y.; Kubo, T.; Noguchi, M. Loss of Heterozygosity on 10q23.3 and Mutation of the Tumor Suppressor Gene PTEN in Benign Endometrial Cyst of the Ovary: Possible Sequence Progression from Benign Endometrial Cyst to Endometrioid Carcinoma and Clear Cell Carcinoma of the Ovary Cancer Res. 2000, 60 (24) 7052-7056
25. Markman, M. CA-125: an Evolving Role in the Management of Ovarian Cancer J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 1996, 14 (5) 1411-1412
26. Kisiel, W.; Sprecher, C. A.; Foster, D. C. Evidence That a Second Human Tissue Factor Pathway Inhibitor (TFPI-2) and Human Placental Protein 5 Are Equivalent Blood 1994, 84 (12) 4384-4385
27. Miyagi, Y.; Koshikawa, N.; Yasumitsu, H.; Miyagi, E.; Hirahara, F.; Aoki, I.; Misugi, K.; Umeda, M.; Miyazaki, K. cDNA Cloning and mRNA Expression of a Serine Proteinase Inhibitor Secreted by Cancer Cells: Identification As Placental Protein 5 and Tissue Factor Pathway Inhibitor-2 J. Biochem. 1994, 116 (5) 939-942
28. Bohn, H.; Winckler, W. [Isolation and characterization of the placental protein pp5 (author's transl)] Arch. Gynakol. 1977, 223 (3) 179-186
29. Sarandakou, A.; Protonotariou, E.; Rizos, D. Tumor Markers in Biological Fluids Associated with Pregnancy Crit. Rev. Clin. Lab. Sci. 2007, 44 (2) 151-178
30. Shinoda, E.; Yui, Y.; Hattori, R.; Tanaka, M.; Inoue, R.; Aoyama, T.; Takimoto, Y.; Mitsui, Y.; Miyahara, K.; Shizuta, Y.; Sasayama, S. Tissue Factor Pathway Inhibitor-2 Is a Novel Mitogen for Vascular Smooth Muscle Cells J. Biol. Chem. 1999, 274 (9) 5379-5384
31. Tanaka, Y.; Utsumi, J.; Matsui, M.; Sudo, T.; Nakamura, N.; Mutoh, M.; Kajita, A.; Sone, S.; Kigasawa, K.; Shibuya, M.; Reddy, V. N.; Zhang, Q.; Iwata, T. Purification, Molecular Cloning, And Expression of a Novel Growth-Promoting Factor for Retinal Pigment Epithelial Cells, REF-1/TFPI-2 Invest. Ophthalmol. Visual Sci. 2004, 45 (1) 245-252
32. Bajaj, M. S.; Birktoft, J. J.; Steer, S. A.; Bajaj, S. P. Structure and Biology of Tissue Factor Pathway Inhibitor Thromb. Haemost. 2001, 86 (4) 959-972
33. Sprecher, C. A.; Kisiel, W.; Mathewes, S.; Foster, D. C. Molecular Cloning, Expression, And Partial Characterization of a Second Human Tissue-Factor-Pathway Inhibitor Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (8) 3353-3357
34. Rao, C. N.; Liu, Y. Y.; Peavey, C. L.; Woodley, D. T. Novel Extracellular Matrix-Associated Serine Proteinase Inhibitors from Human Skin Fibroblasts Arch. Biochem. Biophys. 1995, 317 (1) 311-314
35. Petersen, L. C.; Sprecher, C. A.; Foster, D. C.; Blumberg, H.; Hamamoto, T.; Kisiel, W. Inhibitory Properties of a Novel Human Kunitz-Type Protease Inhibitor Homologous to Tissue Factor Pathway Inhibitor Biochemistry 1996, 35 (1) 266-272
36. Lakka, S. S.; Konduri, S. D.; Mohanam, S.; Nicolson, G. L.; Rao, J. S. In Vitro Modulation of Human Lung Cancer Cell Line Invasiveness by Antisense cDNA of Tissue Factor Pathway Inhibitor-2 Clin. Exp. Metastasis 2000, 18 (3) 239-244
37. Konduri, S. D.; Tasiou, A.; Chandrasekar, N.; Rao, J. S. Overexpression of Tissue Factor Pathway Inhibitor-2 (TFPI-2), Decreases the Invasiveness of Prostate Cancer Cells in Vitro Int. J. Oncol. 2001, 18 (1) 127-131
38. Konduri, S. D.; Rao, C. N.; Chandrasekar, N.; Tasiou, A.; Mohanam, S.; Kin, Y.; Lakka, S. S.; Dinh, D.; Olivero, W. C.; Gujrati, M.; Foster, D. C.; Kisiel, W.; Rao, J. S. a Novel Function of Tissue Factor Pathway Inhibitor-2 (TFPI-2) in Human Glioma Invasion Oncogene 2001, 20 (47) 6938-6945
39. Yanamandra, N.; Kondraganti, S.; Gondi, C. S.; Gujrati, M.; Olivero, W. C.; Dinh, D. H.; Rao, J. S. Recombinant Adeno-Associated Virus (rAAV) Expressing TFPI-2 Inhibits Invasion, Angiogenesis and Tumor Growth in a Human Glioblastoma Cell Line Int. J. Cancer 2005, 115 (6) 998-1005
40. Sato, N.; Parker, A. R.; Fukushima, N.; Miyagi, Y.; Iacobuzio-Donahue, C. A.; Eshleman, J. R.; Goggins, M. Epigenetic Inactivation of TFPI-2 As a Common Mechanism Associated with Growth and Invasion of Pancreatic Ductal Adenocarcinoma Oncogene 2005, 24 (5) 850-858
41. George, J.; Gondi, C. S.; Dinh, D. H.; Gujrati, M.; Rao, J. S. Restoration of Tissue Factor Pathway Inhibitor-2 in a Human Glioblastoma Cell Line Triggers Caspase-Mediated Pathway and Apoptosis Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2007, 13 (12) 3507-3517
42. Ran, Y.; Pan, J.; Hu, H.; Zhou, Z.; Sun, L.; Peng, L.; Yu, L.; Liu, J.; Yang, Z. A Novel Role for Tissue Factor Pathway Inhibitor-2 in the Therapy of Human Esophageal Carcinoma Human Gene Therapy 2009, 20 (1) 41-49
43. Konduri, S. D.; Srivenugopal, K. S.; Yanamandra, N.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; Foster, D. C.; Kisiel, W.; Ali-Osman, F.; Kondraganti, S.; Lakka, S. S.; Rao, J. S. Promoter Methylation and Silencing of the Tissue Factor Pathway Inhibitor-2 (TFPI-2), a Gene Encoding an Inhibitor of Matrix Metalloproteinases in Human Glioma Cells Oncogene 2003, 22 (29) 4509-4516
44. Rao, C. N.; Segawa, T.; Navari, J. R.; Xu, L.; Srivastava, S.; Moul, J. W.; Phillips, B. Methylation of TFPI-2 Gene Is Not the Sole Cause of Its Silencing Int. J. Oncol. 2003, 22 (4) 843-848
45. Sierko, E.; Wojtukiewicz, M. Z.; Kisiel, W. The Role of Tissue Factor Pathway Inhibitor-2 in Cancer Biology Semin. Thromb. Hemost. 2007, 33 (7) 653-659
46. Steiner, F. A.; Hong, J. A.; Fischette, M. R.; Beer, D. G.; Guo, Z. S.; Chen, G. A.; Weiser, T. S.; Kassis, E. S.; Nguyen, D. M.; Lee, S.; Trepel, J. B.; Schrump, D. S. Sequential 5-Aza 2′-Deoxycytidine/Depsipeptide FK228 Treatment Induces Tissue Factor Pathway Inhibitor 2 (TFPI-2) Expression in Cancer Cells Oncogene 2005, 24 (14) 2386-2397